Nucleic acids encoding humanized anti-tag 72 CC49 antbodies

Details Nucleic acids encoding humanized anti-tag 72 CC49 antbodies Nucleic acids encoding humanized anti-tag 72 CC49 antbodies

2011-04-05

2011-04-05

Blanchard, David J. (Department: 1643)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C424S133100, C424S141100, C424S155100, C424S178100, C435S069600, C435S235100, C435S320100, C435S328000, C530S387300, C530S388100, C530S388800, C530S391300

Reexamination Certificate

active

07919607

ABSTRACT:
The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5472693 (1995-12-01), Gourlie et al.
patent: 5482040 (1996-01-01), Martin, Jr.
patent: 5512443 (1996-04-01), Schlom et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5688657 (1997-11-01), Tsang et al.
patent: 5976531 (1999-11-01), Mezes et al.
patent: 5976845 (1999-11-01), Mezes et al.
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6333405 (2001-12-01), Anderson et al.
patent: 6495137 (2002-12-01), Mezes et al.
patent: 7081518 (2006-07-01), Pastan et al.
patent: 2131355 (2001-04-01), None
patent: 2068593 (2003-07-01), None
patent: 0239400 (1987-09-01), None
patent: 0365997 (1990-05-01), None
patent: WO 89/00692 (1989-01-01), None
patent: WO 89/01783 (1989-05-01), None
patent: WO 90/04410 (1990-05-01), None
patent: WO 91/00295 (1991-01-01), None
patent: WO 93/12231 (1993-06-01), None
patent: WO 96/13594 (1996-05-01), None
patent: WO 97/26010 (1997-07-01), None
patent: WO 98/18809 (1998-05-01), None
patent: WO 99/43816 (1999-02-01), None
patent: WO 00/26394 (2000-05-01), None
patent: WO 2005/021594 (2005-03-01), None
Iwahashi et al. Molecular Immunology, 1999. 36:1079-1091.
Abergel et al., “Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab′,”Proteins: Structure, Function, and Genetics17:438-443, 1993.
Adams and Schier, “Generating improved single-chain Fv molecules for tumor targeting,”Journal of Immunological Methods, 231(1-2):249-260, 1999.
Bending, “Humanization of Rodent Monoclonal Antibodies by CDR Grafting,”Methods: A Companion to Methods in Enzymology, 8:83-93 (1995).
Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,”Biomedical and Biophysical Research Communications, 307:198-205 (2003).
Colcher et al., “Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies,”Cancer Research48:4597-4603, Aug. 15, 1988.
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,”Research in Immunology, 145:33-36 (1994).
De Pascalis et al., “In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants,”Clin. Can. Res. 9:5521-5531 (2003).
De Pascalis et al., “In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants,”Clinical Cancer Research, 9(15):5521-5531 (2003).
De Pascalis et al.,“Grafting of ”abbreviated“ complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody,”J. Immunol. 169:3076-3084 (2002).
Divgi et al., “Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen,”Nucl. Med. Biol. 21(1):9-15 (1994).
Gonzales et al., “Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues,”Mol. immunol.40:337-349 (2003).
Hakimi et al., “Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys,”J. Immunol. 147:1352-1359 (1991).
Hand et al., “Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma,”Cancer Supplement73(3):1105-1113, Feb. 1, 1994.
Iwahashi et al., “CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity,”Mol. Immunol. 36:1079-1091 (1999).
Johnson et al., “Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3,”Cancer Research46:850-857, Feb. 1986.
Jones et al., “Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse,”Nature321:522-525, May 29, 1986.
Kashmiri et al., “Development of a minimally immunogenic variant of humanized anticarcinoma monoclonal antibody CC49,”Crit. Rev. Oncol. Hematol. 38:3-16 (2001).
Kashmiri et al., “Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49,”Hybridoma14(5):461-473 (1995).
Kashmiri et al., Chapter 21 inMethods in Molecular Biology, vol. 248:Antibody Engineering: Methods and Protocols, p. 361-376; Lo (ed.), Humana Press, Inc., Tolowa, NJ (2003).
**Kashmiri et al., “SDR grafting—a new approach to antibody humanization,”Methods, 36:25-34, 2005.
MacCallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Typography,”J. Mol. Biol., 262:732-745 (1996).
Mulligan et al., “Phase I Study of Intravenous177Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma,”Clinical Cancer Research1:1447-1454, Dec. 1995.
Muraro et al., “Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen,”Cancer Research48:4588-4596, Aug. 15, 1988.
Osbourn et al., “Generation of a panel of related human scFv antibodies with high affinities for human CEA,”Immunotechnology, 2(3):181-196 (1996).
Padlan et al., “Identification of Specificity-determining Residues in Antibodies,”The FASEB Journal9:133-139, Jan. 1995.
Padlan, “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties,”Molecular Immunology28(4/5):489-498 (1991).
Padlan, “Anatomy of the antibody molecule,”Mol. Immunol. 31:169-217 (1994).
Paul,Fundamental Immunology, Raven Press, NY, Ch. 8, p. 242 (1993).
Reichman et al., “Reshaping human antibodies for therapy,”Nature(London) 332:323-327 (1988).
Rixon et al., “Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies,”The Journal of Immunology151(11):6559-6568, Dec. 1, 1993.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,”Proc Natl Acad Sci U S A. Mar.; 79(6): 1979-1983 (1982).
Saldanha et al., “A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells,”Mol. Immunol. 36:709-719 (1999).
Schier et al., “Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site,”J. Mol. Biol. 263:551-567 (1996).
Sha et al., “A heavy-chain grafted antibody that recognizes the tumor-associated TAG72 antigen,”Cancer Biother. 9(4):341-349 (1994).
Sharkey et al., “Evaluation of a complementarity-determining region-grafted (humanized) anti

Affiliated with

Also associated with

Rating

Nucleic acids encoding humanized anti-tag 72 CC49 antbodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acids encoding humanized anti-tag 72 CC49 antbodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding humanized anti-tag 72 CC49 antbodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2652076